At the Herbert Irving Comprehensive Cancer Center at Columbia University and NewYork-Presbyterian Hospital, we believe that our discoveries here will end cancer everywhere.
Working together, we empower innovation and discovery in prevention, research and clinical care to reduce the burden of cancer for our patients, our community, and the world.
January 04, 2021
Video
Naiyer A. Rizvi, MD, discusses the use of biomarkers to select patients with non–small cell lung cancer for treatment with immunotherapy.
November 18, 2020
Video
Naiyer A. Rizvi, MD, discusses the rationale to evaluate the investigational glutaminase inhibitor telaglenastat in patients with non–small cell lung cancer who harbor KEAP1 or NRF2 mutations.
October 22, 2020
Video
Gary K. Schwartz, MD, discusses the benefit of dose reducing ipilimumab plus nivolumab in metastatic sarcomas.
October 19, 2020
Article
Telaglenastat, a novel drug that targets a key metabolic pathway, has shown encouraging antitumor activity in several cancer types.
October 15, 2020
Video
Gary K. Schwartz, MD, discusses future research efforts in the field of sarcoma.
September 17, 2020
Article
Timothy Cragin Wang, MD, discusses the advent of immunotherapy and how it has revolutionized multiple areas of cancer treatment; however, the transformative potential of the modality has been mild in the field of colorectal cancer.